Non-coding RNA in Hematological Cancers
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (1 February 2021)
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue covers all types of non-coding RNAs in hematological cancers.
Understanding the roles of ncRNAs blood cancers is essential and can provide insight into the development of diagnosis, prognosis, and treatment modalities. Approximately every 3 minutes, one person in the USA diagnosed with a blood cancer, with an estimated total of cases in 2020 standing at 178,520 for leukemia, lymphoma, and myeloma, which is approximately 9.9% of total cancers diagnosed in USA for the year 2020 (American Cancer Society, 2020).
Non-coding RNAs (ncRNAs) or small non-coding RNAs (sncRNAs) are broadly distributed and implicated in many diseases, including blood cancers. These ncRNAs play crucial roles in blood cancer development, progression, metastasis, chemoresistance, and many more. Small RNAs consist of 17–250 nucleotides in length; among them, microRNAs (miRNAs, 17–24 nucleotides) are the most studied and well known non-coding RNAs. Piwi-interacting RNAs (piRNAs, 26-33 nucleotides) are the largest class of the small non-coding RNA family and are implicated in epigenetic and post-transcriptional regulation but still lack functional characterization. Long non-coding RNAs (lncRNAs, more than 200 nucleotides) are a diverse class of RNAs, believed to play an important role in cellular mechanisms; however, little biological relevance has been established thus far. Circular RNAs (circRNAs, 100 nt to 4 kb) are a recently rediscovered RNA class of non-coding RNAs, which were initially described as scrambled exons. They are resistant to endonuclease treatment and are highly stable. Small nuclear/nucleolar RNAs (sn/snoRNAs, 70–120 nucleotides) are perhaps the most ancient and highly conserved class of sncRNAs, carrying out a fundamental role in the modification and processing of ribosomal RNAs (rRNA), transfer RNAs (tRNA), and small nuclear RNAs (snRNA).
Dr. Srinivas V Koduru
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hematological cancers
- Myeloma
- AML
- microRNAs
- ncRNAs
- Non-coding RNAs
